According to a Phase 3 clinical trial (INTEGUMENT-PED) roflumilast cream 0.05% is effective and safe for children aged 2-5 ...

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting ...

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Discover expert methods to identify, treat and prevent various types of skin rashes, from allergic reactions to chronic ...

When the baby has a diaper rash, it means there is dermatitis trouble. The skin areas near the diaper face redness. Rashes ...

ZORYVE's rapid sales growth positions Arcutis Biotherapeutics as a strong buy with profitability expected in 12 months. Read ...

Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...